Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Li C, Xu J, Luo W, Liao D, et al. Leukemia 2024;38:149-159.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li C, Xu J, Luo W, Liao D, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia 2024;38:149-159.
PMID: 37848634